Navigation Links
Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
Date:3/6/2008

patients and associated with increased risk of cardiovascular morbidity and mortality. Sevelamer provides the added benefit of significant LDL cholesterol reduction.

Sevelamer is the only phosphate binder available that does not contain either calcium or a metal. It has an established safety profile, is not systemically absorbed and provides phosphorus control without the concerns of calcium or metal accumulation. The National Kidney Foundation's 2003 Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines for Bone Metabolism and Disease in CKD recommend sevelamer as a first-line treatment option to control phosphorus. Sevelamer hydrochloride is currently used by more than 350,000 patients worldwide.

Product Information

Renvela (sevelamer carbonate) and Renagel (sevelamer hydrochloride) are indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis. Sevelamer is contraindicated in patients with hypophosphatemia or bowel obstruction. Caution should be exercised in patients with dysphagia, swallowing disorders, severe gastrointestinal (GI) motility disorders including severe constipation or major GI tract surgery. Common adverse events reported with sevelamer include vomiting, nausea, diarrhea, dyspepsia, abdominal pain, and constipation. Other events reported include pruritus, rash, fecal impaction, and intestinal obstruction. Drug- drug interactions may occur with some medications and should be taken into consideration when instructing patients how to take sevelamer. Patients should be informed to take sevelamer with meals and to adhere to their prescribed diets. For more information on Renvela or Renagel, please see Full Prescribing Information, call Genzyme Medical Information at 1-800-847-0069 or visit http://www.renagel.com or http://www.renvela.com

About Genzyme

One of the wor
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
2. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
3. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
4. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
5. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
6. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
7. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
8. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
9. Genzyme Launches Cholestagel(R) in Europe
10. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
11. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)...Newswire/ -- BioTrends Research Group, Inc.,releas...M) publication, a,syndicated report offering compr...ia and bone and mineral metabolism in Chronic Kidn... information from 182 US,Nephrologists -- data wer...ne 2008., In the renal anemia market, while the u...
(Date:7/25/2008)...X, CALGARY, July 25 / Resv...X:RVX) is pleased to announce effective,immediatel...irectors. On,the subject of her appointment Jan Gr...xciting opportunity for me. The Company has done a...linical trials. I expect the next,foreseeable futu...
(Date:7/25/2008)...swire-FirstCall/ -- Caraco Pharmaceutical,Laborato...first quarter of,Fiscal 2009, ended June 30, 2008,...or the corresponding period of Fiscal 2008. This r...er of Fiscal 2008. Pre-tax income grew,to $14.6 mi...ared to a,pre-tax income of $9.6 million during th...
(Date:7/25/2008)...25 /- REvolution Computing will,lead ...R product at the,upcoming BioC 2008 conference in ... REvolution Computing Director of Community, Dr. D... Training Manager, and Martin Morgan of,the Fred H...ting,s BioC lab,will introduce participants to the...
Breaking Biology Technology:BioTrends Releases Quarterly TreatmentTrends(TM): Nephrology Report Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism 2BioTrends Releases Quarterly TreatmentTrends(TM): Nephrology Report Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism 3Jan Gray Joins Resverlogix Board of Directors 2Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 2Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 3Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 4Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 5Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 6Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009 7REvolution Computing Offers Hands-On Tutorial of NWS Parallel Computing Environment at BioC 2008 2
...its of switching to voice over Internet protocol (...at the Italian Community Center in Milwaukee. Near... users share their experiences with VoIP. , ,Clear...erry Rocco, Cisco Systems, and Pat Scheckel, VoIP ...Brian Carlson, manager network/communications for ...
...ence faculty at the University of Wisconsin-Eau Cl...h more opportunities to work on research relating ...e university to assist local industries. , ,UW-Eau...ll support research, facilitate collaboration amon...ractions between the university and local industri...
...Julius truly cares about me. He often sends me sto...as for how to buy prescription drugs on the cheap....duction. Ursula seems more interested in enlargeme...up in the From line of my e-mail every day, usuall...in the morning is cleaning out unsolicited message...
...roadcast Systems and Madison-based MyWeather LLC...tion that alerts for breaking news and severe weat...ated television stations. , ,Powered by MyWeather ...imely information to people while they are at work... Desktop Alert to proactively grab viewers attenti...
Other Biology Technology:VoIP: Are we there yet? 2UW-Eau Claire creates Materials Science Center 2UW-Eau Claire creates Materials Science Center 3Putting spam back in the can wont be all that easy 2
(Date:7/24/2008)...tate University College of Medicine, Hershey, Penn...uimod, a clinically important immune response modi... is dependent on the Opioid Growth Factor (OGF)-OG...very, reported in the August 08 issue of Experime...into a widely used drug that may lead to developme...
(Date:7/24/2008)... talk, they might tell potential suitors, "I like ...come slither look. But worms send their valentines...al code researchers are now cracking, according to...nal Nature . , Scientists from the University ...titute of Technology and the U.S. Department of Ag...
(Date:7/24/2008)...uced carbon storage in western U.S. forests , A...entury has caused a widespread increase in fire-in...stems growing on trees within western U.S. forests...re thought to account for much of North America,s ...ound biomass, Fellows and Goulden compare Californ...
(Date:7/23/2008)...together internationally renowned scientists from ...apan, Australia and India to address ancient micr...e are bringing together the world,s best scientist...izer J. William Schopf, founder and director of th...cs, Center for the Study of Evolution and the Orig...
Breaking Biology News(10 mins):Imiquimod, an immune response modifier, is dependent on the OGF-OGFr signaling pathway 2Mate or hibernate? That's the question worm pheromones answer 2Mate or hibernate? That's the question worm pheromones answer 3AGU journal highlights -- July 23, 2008 2AGU journal highlights -- July 23, 2008 3AGU journal highlights -- July 23, 2008 4AGU journal highlights -- July 23, 2008 5AGU journal highlights -- July 23, 2008 6AGU journal highlights -- July 23, 2008 7AGU journal highlights -- July 23, 2008 8UCLA 'world summit' to explore ancient life on Earth, and beyond 2King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion 5063 1King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion 5063 2King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion 5063 3King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion 5063 4King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion 5063 5King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion 5063 6Once Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head to Head Study 5059 1Once Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head to Head Study 5059 2Once Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head to Head Study 5059 3Once Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head to Head Study 5059 4Once Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head to Head Study 5059 5Once Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head to Head Study 5059 6Once Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head to Head Study 5059 7Once Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head to Head Study 5059 8Amylin Pharmaceuticals to Webcast Conference Call 5055 1Amylin Pharmaceuticals to Webcast Conference Call 5055 2Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman 26 Renshaw Healthcare Conference 1603 1Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman 26 Renshaw Healthcare Conference 1603 2
...s has,found the first clear evidence that the proc...ility to recognize and respond to a million,differ...f genes whose,only apparent function is to jump ar...ially cut themselves out of the genetic material, ...ght have been borrowed by cells,needing to build m...
...or of Research at the Molecular Sciences Institut... approach to simulation of intracellular,biochemic...Biotechnology.,The research article, entitled "Au...ith Moleculizer 1.0" (pdf) ,describes MSI,s discre...f the thousands of complex species formed from pat...
...em the rising rate of HIV infection, warn two seni...An estimated 38 million people worldwide, includin...IV, and a record 4.8 million became infected in 20...ncrease is socioeconomic, but the increase also re...s. , For instance, the search for a vaccine agains...
...al nervous system (CNS), where it influences neuro...an now use microarray technology to study brain fu...ed in the February issue of Alcoholism: Clinical &...alcohol on what is called "gene expression" in the... have exactly the same deoxyribonucleic acid (DNA)...
Other Biology News:Jumping gene helps explain immune system's abilities 2Jumping gene helps explain immune system's abilities 3MSI releases 'moleculizer' - a new approach to simulation of intracellular biochemical networks 2MSI releases 'moleculizer' - a new approach to simulation of intracellular biochemical networks 3Alcohol's effects on gene expression in the central nervous system 2Alcohol's effects on gene expression in the central nervous system 3Alcohol's effects on gene expression in the central nervous system 4
Cytofix/Cytoperm Kit 250 Tests
The BD PhosFlow Fix Buffer I can be used for the simultaneous fixation and permeabilization of cells prior to intracellular staining. Applications: Intracellular Staining (Flow) Storage Temperature:
Anti-MAGE-D2/NRAGE-Like 2b GenBank Accession Number : NM_201222 Immunogen : peptide (C-QSQENQDTRPKVKAKK), corresponding to amino acids 161-176 of human MAGE-D2/NRAGE-Like 2b Formulation: antiserum
Request Info
Biology Products: